Trial intelligence / Profile preview

CBP-201 in Moderate to Severe Persistent Asthma

NCT04773678Phase 2Completed

Sponsor
Connect Biopharma
Start
May 2021
Primary completion
Aug 2023
Modality
Monoclonal Antibodies
Countries
5
01

Overview

A Phase 2 trial of rademikibart in asthma, sponsored by Connect Biopharma. Started May 2021; status: completed.

02

Drugs

rademikibart
03

Conditions

asthma

Beyond the preview

Go deeper on NCT04773678.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT04773678.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call